CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study Active SB-P Versus Conventional Approach to the Protection of High-Risk Side Branches: The CIT-RESOLVE Trial Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study EXCELling in Left Main Intervention Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study Impact of intravascular ultrasound guidance in routine percutaneous coronary intervention for conventional lesions: data from the EXCELLENT trial Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials

Expert Opinion

JOURNAL:ACC Article Link

Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis - RECOVERY

Dharam J. Kumbhani

Pre-reading

CONTRIBUTION TO LITERATURE - The RECOVERY trial showed that early surgery among patients with asymptomatic but very severe aortic stenosis results in improved survival out to 8 years compared with watchful waiting.


DESCRIPTION - The goal of the trial was to assess the safety and benefit of surgery vs. watchful waiting among patients with asymptomatic very severe aortic stenosis.


STUDY DESIGN

Eligible patients with very severe asymptomatic aortic stenosis were randomized in a 1:1 open-label fashion to either early surgical aortic valve replacement (AVR) (n = 73) or watchful waiting (n = 72).

- Total screened: 273

- Total number of enrollees: 145

- Duration of follow-up: 6.2 years

- Mean patient age: 64.2 years

- Percentage female: 51%


INCLUSION CRITERIA:

- Age 20-80 years

- Very severe aortic stenosis (aortic valve area [AVA] 0.75 cm2, peak velocity 4.5 m/sec, or mean gradient 50 mm Hg)

- Lack of symptoms


EXCLUSION CRITERIA:

- Exertional dyspnea, syncope, presyncope, or angina

- Left ventricular ejection fraction (LVEF) <50%

- Clinically significant aortic regurgitation or mitral valve disease

- Prior cardiac surgery

- Positive cardiac stress test

- Medical conditions such as cancer


OTHER SALIENT FEATURES/CHARACTERISTICS:

- Body mass index: 24.5 kg/m2

- Coronary artery disease: 4-5%

- Mean EuroSCORE II: 0.9%

- Cause of aortic stenosis: bicuspid valve: 60%, degenerative: 33%, rheumatic: 6%

- Peak velocity: 5.1 m/sec, mean gradient 64 mm Hg, AVA 0.64 cm2

- Mean LVEF: 65%


PRINCIPAL FINDINGS -

The primary outcome of operative mortality or cardiovascular mortality at 4 years, for early surgery vs. watchful waiting, was 1% vs. 6% (p < 0.05). At 8 years: 1% vs. 26% (p = 0.003).

- Cardiovascular mortality at 4 years: 1% vs. 15% (hazard ratio 0.09, 95% confidence interval 0.01-0.67, p < 0.05)

SECONDARY OUTCOMES FOR EARLY SURGERY VS. WATCHFUL WAITING:

- All-cause mortality at 8 years: 10% vs. 32% (p < 0.05)

- Heart failure hospitalization: 0% vs. 11% (p < 0.05)

- Any secondary endpoint or AVR in watchful waiting group: 62% at 4 years, 92% at 8 years


INTERPRETATION - The results of this trial indicate that early surgery among patients with asymptomatic but very severe aortic stenosis (AVA 0.75 cm2, mean gradient 50 mm Hg, peak velocity 4.5 m/sec) results in improved survival out to 8 years compared with watchful waiting. These are important findings, and will likely change guidelines on this topic. Currently, surgery for asymptomatic aortic stenosis has a Class IIb indication in the American Heart Association/American College of Cardiology valvular heart disease guideline. There are observational data that patients with peak velocity >5 m/sec may particularly benefit, especially if they are low-surgical risk candidates.

A few noteworthy points: Although the surgical risk of these patients was low, there were zero operative deaths, which is likely a reflection of experienced operators/institutions. The generalizability of these findings may thus be harder in a more heterogeneous landscape such as in the United States. Also, it is interesting to note that patients in the watchful waiting arm could go as long as 8 years without crossing over (only two cross-overs to surgery), despite having such severe aortic stenosis. Other studies have suggested this latentperiod (i.e., no symptoms despite severe aortic stenosis) to be about 1-2 years. This cohort had a very high proportion of bicuspid aortic stenosis patients, which may be a partial reason for this. Also, exercise testing was only selectively employed; thus, some patients could have hiddensymptomatic aortic stenosis, which would have been unmasked with a stress test. The EARLY-TAVR trial is looking to enroll a similar asymptomatic population all patients are required to undergo exercise testing for this reason. Finally, these results are not applicable to TAVR; EARLY-TAVR and other studies will help inform this question.